Methionine restriction or MAT2A inhibitor SCR6639 increases CD8A+ T cell infiltration in the tumor microenvironment, enhancing the efficacy of immune checkpoint therapy in MTAP-deleted osteosarcoma. This evidence concerns the gene CD8A and osteosarcoma.